Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 139,700 Shares of Edwards Lifesciences Corporation $EW

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 104.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 273,735 shares of the medical research company’s stock after buying an additional 139,700 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Edwards Lifesciences were worth $21,921,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Elevation Point Wealth Partners LLC increased its position in Edwards Lifesciences by 43.2% during the first quarter. Elevation Point Wealth Partners LLC now owns 11,325 shares of the medical research company’s stock worth $907,000 after acquiring an additional 3,416 shares during the period. Platform Technology Partners bought a new stake in Edwards Lifesciences in the 1st quarter valued at $244,000. Sound Income Strategies LLC boosted its holdings in Edwards Lifesciences by 257.4% in the 1st quarter. Sound Income Strategies LLC now owns 890 shares of the medical research company’s stock valued at $72,000 after purchasing an additional 641 shares during the period. Boston Trust Walden Corp grew its position in Edwards Lifesciences by 6.0% in the 1st quarter. Boston Trust Walden Corp now owns 282,950 shares of the medical research company’s stock worth $22,659,000 after purchasing an additional 16,045 shares during the last quarter. Finally, Keybank National Association OH increased its holdings in shares of Edwards Lifesciences by 14.2% during the 1st quarter. Keybank National Association OH now owns 38,717 shares of the medical research company’s stock worth $3,100,000 after purchasing an additional 4,809 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Robert W. Baird upped their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Tuesday, June 16th. Finally, Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.39.

Insider Buying and Selling

In other news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 58,977 shares of company stock valued at $4,921,803. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 0.1%

EW stock opened at $94.31 on Friday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $94.47. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $85.61 and its 200-day moving average is $83.57. The firm has a market cap of $54.31 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.37 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.